Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor

Withdrawn

• Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor; Rhabdoid Tumor of the Kidney
• Interventions: Other: Laboratory Biomarker Analysis

• Registration Number: NCT01453465
• Lead Sponsor: Children's Oncology Group

Brief Summary

This research trial studies biomarkers in samples from patients with rhabdoid tumor of the kidney and atypical teratoid rhabdoid tumor. Studying biomarkers of tissue samples from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine if there are molecular differences between rhabdoid tumor of the kidney (RTK) and the atypical teratoid rhabdoid tumor (ATRT).

OUTLINE:

Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.

Study Timeline

• Study First Submitted: 2011-10-01
• Study First Submitted QC: 2011-10-14
• Study First Posted: 2011-10-17
• Study Start: 2011-11-01
• Primary Completion: 2011-12-01
• Status Verified: 2017-10
• Last Update Submitted: 2018-08-03
• Last Update Posted: 2018-08-07

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Samples of RTK and ATRT provided by the Children?s Oncology Group (COG)

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Ancillary-Correlative (gene expression profile, miRNA profile)	Laboratory Biomarker Analysis	Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.

Primary Outcome Measures

Name	Time	Method
Molecular differences between RTK and the ATRT	Up to 3 months

Trial Locations

Locations (1)

Childrens Oncology Group; 🇺🇸 Philadelphia, Pennsylvania, United States